Telogen effluvium is reversible
Retatrutide continues to be evaluated in additional Phase 3 studies across obesity and obesity-related conditions, including knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease (MASLD)
Plans are more likely to cover a GLP-1 for an FDA-approved use such as type 2 diabetes, and many employer plans still exclude weight-loss coverage entirely
These compounds can enhance GLP-1 secretion via various mechanisms
Many researchers who transition from tirzepatide to retatrutide find the side effect timing quite similar since both medications share the GIP pathway
Some women find that stepping back to a lower dose and titrating up more slowly resolves the issue without sacrificing weight loss efficacy